A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

Sponsor
Changzhi People's Hospital Affiliated to Changzhi Medical College
Study ID
NCT06485271
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    200mg,iv,d1,Q2W/Q3W
  • apatinib — DRUG
    250mg,qd
  • chemotherapy — DRUG
    Standard treatment

Study Details

The purpose of this observational study is to evaluate the safety and efficacy of camrelizumab and apatinib in patients with advanced gastric cancer under real-life conditions, particularly in various subgroups of gastric cancer patients, with a view to providing information about the treatment modalities and efficacy of the treatment in real-life gastric cancer patients and to explore the possible predictive biomarkers of prognosis.Patients, who had both decided to be treated with camrelizumab or apatinib prior to enrollment, were entered into one of the following three cohorts at the discretion of the investigator, based on their disease stage and prior treatment

Key Dates

Start date
Nov 1, 2023
Status verified
Jun 2024
Primary completion
Oct 31, 2025
Completion
Oct 31, 2026

Study Design

Enrollment
504 participants (estimated)

Arms

  • Arm: cohort 1
    First-line
  • Arm: cohort 2
    Second-line
  • Arm: cohort 3
    Third-line and above

Primary Outcome Measure

Objective response rate [ Time Frame: 24 months ]

Related Studies